The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index; none of the 15 sources its claims cite is checked for support yet.
Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
Open accessAbstract
IMPORTANCE: Targeting oncogenic drivers (genomic alterations critical to cancer development and maintenance) has transformed the care of patients with lung adenocarcinomas. The Lung Cancer Mutation Consortium was formed to perform multiplexed assays testing adenocarcinomas of the lung for drivers in 10 genes to enable clinicians to select targeted treatments and enroll patients into clinical trials. OBJECTIVES: To determine the frequency of oncogenic drivers in patients with lung adenocarcinomas and to use the data to select treatments targeting the identified driver(s) and measure survival. DESIGN, SETTING, AND PARTICIPANTS: From 2009 through 2012, 14 sites in the United States enrolled patients with metastatic lung adenocarcinomas and a performance status of 0 through 2 and tested their tumors for 10 drivers. Information was collected on patients, therapies, and survival. INTERVENTIONS: Tumors were tested for 10 oncogenic drivers, and results were used to select matched targeted therapies. MAIN OUTCOMES AND MEASURES: Determination of the frequency of oncogenic drivers, the proportion of patients treated with genotype-directed therapy, and survival. RESULTS: From 2009 through 2012, tumors from 1007 patients were tested for at least 1 gene and 733 for 10 genes (patients with full genotyping). An oncogenic driver was found in 466 of 733 patients (64%). Among these 733 tumors, 182 tumors (25%) had the KRAS driver; sensitizing EGFR, 122 (17%); ALK rearrangements, 57 (8%); other EGFR, 29 (4%); 2 or more genes, 24 (3%); ERBB2 (formerly HER2), 19 (3%); BRAF, 16 (2%); PIK3CA, 6 (<1%); MET amplification, 5 (<1%); NRAS, 5 (<1%); MEK1, 1 (<1%); AKT1, 0. Results were used to select a targeted therapy or trial in 275 of 1007 patients (28%). The median survival was 3.5 years (interquartile range [IQR], 1.96-7.70) for the 260 patients with an oncogenic driver and genotype-directed therapy compared with 2.4 years (IQR, 0.88-6.20) for the 318 patients with any oncogenic driver(s) who did not receive genotype-directed therapy (propensity score-adjusted hazard ratio, 0.69 [95% CI, 0.53-0.9], P = .006). CONCLUSIONS AND RELEVANCE: Actionable drivers were detected in 64% of lung adenocarcinomas. Multiplexed testing aided physicians in selecting therapies. Although individuals with drivers receiving a matched targeted agent lived longer, randomized trials are required to determine if targeting therapy based on oncogenic drivers improves survival. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01014286.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
22 Own result · 11 Own method · 5 Not checked yet · 5 Own interpretation · 1 No basis given
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“2 or more genes, 24 (3%)”
- Also stated in: § Results · plain
“we found drivers in 2 genes in 24 tumors (3%).”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Abstract > RESULTS
plainn = 24- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Results · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The 190 patients with an oncogenic driver and treatment with a targeted agent had a median survival of 3.5 years (IQR, 1.96-7.70); the 248 with a driver and no targeted therapy, 2.5 years (P < .001”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Results
plaincorrelationaln = 190 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“ERBB2 (formerly HER2), 19 (3%)”
- Also stated in: § Results · plain
“The frequencies of ERBB2 (all exon 20 insertions) were 3% (19 of 733 specimens)”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Abstract > RESULTS
plainn = 733- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Results · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The median survival was 3.5 years (interquartile range [IQR], 1.96-7.70) for the 260 patients with an oncogenic driver and genotype-directed therapy compared with 2.4 years (IQR, 0.88-6.20) for the 318 patients with any oncogenic driver(s) who did not receive genotype-directed therapy”
- Also stated in: § Results · plain
“The 260 patients with an oncogenic driver and treatment with a targeted agent had a median survival of 3.5 years; the 318 patients with a driver and no targeted therapy, 2.4 years”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Abstract > RESULTS
plaincorrelationaln = 260 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Results · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“ALK rearrangements, 57 (8%)”
- Also stated in: § Results · plain
“ALK rearrangements occurred in 57 of 733 specimens (8%).”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Abstract > RESULTS
plainn = 733- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Results · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“An oncogenic driver was found in 466 of 733 patients (64%).”
- Also stated in: § Results · plain
“Among the 733 specimens tested for all 10 genes, 466 (64% [95% CI, 60%-67%) had an oncogenic driver”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Abstract > RESULTS
plainn = 733- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Results · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among these 733 tumors, 182 tumors (25%) had the KRAS driver”
- Also stated in: § Results · plain
“KRAS mutations were the most frequent, found in 182 of 733 specimens (25%)”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Abstract > RESULTS
plainn = 733- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Results · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Overall, 28% (95% CI, 24%-30%) of eligible patients and 44% of individuals with drivers detected received a targeted therapy.”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The frequencies of drivers in the 1007 specimens in which at least 1 gene was assessed are presented in Table 2 and mirror the results with the patients’ tumors with full genotyping.”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Results
plainn = 1,007- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“BRAF, 16 (2%)”
- Also stated in: § Results · plain
“BRAF mutations were 2% (16 of 733 specimens)”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Abstract > RESULTS
plainn = 733- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Results · plain
- The quote only partly states this claim. 1
- It may state two separate claims as one. 8
- Probably not a substantial claim. 9
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“other EGFR, 29 (4%)”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Abstract > RESULTS
plaincorrelationaln = 733- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The quote only partly states this claim.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The LCMC characterized at least 1 gene for 91% (1007 of 1102 patients) of eligible patients with genotyping of all 10 genes in 66% (733 of 1102 patients).”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Discussion
plainn = 1,102- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The median potential follow-up was 2.0 years.”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Results
plainn = 938- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The 49 patients with oncogenic drivers other than EGFR or ALK who received a targeted therapy had a median survival of 4.9 years compared with the 678 with (318 patients) or without (360 patients) a driver identified, but not receiving a targeted agent, whose median survivals were 2.4 years with a driver (IQR, 0.88-6.20) and 2.1 years without (P = .14”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Results
plainn = 49- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Of the 175 patients (83%) with EGFR(s) mutations, 146 were treated with targeted therapy: 130 with erlotinib alone, and 16 with another EGFR inhibitor alone or in combination.”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Results
plainn = 175- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Patients in the driver + treatment group had a 5% better performance status, a 3-year lower median age, and were more likely to be never smokers (Table 1); factors that could lead to an improved prognosis.”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Discussion
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Multiplexed testing aided physicians in selecting therapies.”
- Also stated in: § Conclusions · plain
“Multiplexed testing aided physicians in selecting therapies and patients for targeted trials.”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Abstract > CONCLUSIONS AND RELEVANCE
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Also stated in: § Conclusions · plain
None of the sources cited for this claim have been checked yet.
In the paper
“Testing for somatic mutations in the epidermal growth factor receptor (EGFR) gene4-6 and rearrangements of the anaplastic lymphoma kinase (ALK) gene7 is now routine.8”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Abstract > CONCLUSIONS AND RELEVANCE
What the sources say
- Not checked yetcites [4] Lynch TJ Bell DW Sordella R Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib N Engl J Med 2004 350 21 2129 2139 15118073
- Not checked yetcites [5] Paez JG Jänne PA Lee JC EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 2004 304 5676 1497 1500 15118125
- Not checked yetcites [6] Pao W Miller V Zakowski M EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib Proc Natl Acad SciUS A 2004 101 36 13306 13311 PMC516528 15329413
- Not checked yetcites [7] Kwak EL Bang YJ Camidge DR Anaplastic lymphoma kinase inhibition in non-small cell lung cancer N Engl J Med 2010 363 18 1693 1703 20979469 PMC3014291
- Not checked yetcites [8] National Comprehensive Cancer Network NCCN clinical practice guidelines in oncology 2014 http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed April 21
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Adenocarcinoma was centrally confirmed.”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Methods > Patients
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The LCMC clinical committee chairs reviewed the records of each patient with an oncogenic driver and the targeted agent administered to verify that the treatment was directed against that driver(s) detected in the patient’s tumor.”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Methods > Interventions
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“With the proposed sample size of 1000, the half-width of the 95% CI is less than 5% if the oncogenic driver rate is less than 40%.”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Methods > Statistical Methods
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The decision to recommend a targeted therapy to a patient with a tumor harboring an oncogenic driver was left to the treating physician.”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Methods > Interventions
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The knowledge-based confounding variables adjusted in the propensity model were sex, age at enrollment, performance status, smoking history, stage at diagnosis, prior therapy (surgery, chest radiotherapy, or chemotherapy), and elapsed time from metastatic disease diagnosis to study enrollment (years).”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Methods > Statistical Methods
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Criteria for specimen adequacy were not prespecified.”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Methods > Interventions
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“The LCMC effort differs from other genomic characterization efforts, like the Cancer Genome Atlas that studied patients with localized disease and obtained tissues exclusively from resection specimens.35-40”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Discussion
What the sources say
- Not checked yetcites [35] Weir BA Woo MS Getz G Characterizing the cancer genome in lung adenocarcinoma Nature 2007 450 7171 893 898 17982442 PMC2538683
- Not checked yetcites [36] Barletta JA Perner S Iafrate AJ Clinical significance of TTF-1 protein expression and TTF-1 gene amplification in lung adenocarcinoma J Cell Mol Med 2009 13 8B 1977 1986 19040416 PMC2830395
- Not checked yetcites [37] Hammerman PS Sos ML Ramos AH Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer Cancer Discov 2011 1 1 78 89 22328973 PMC3274752
- Not checked yetcites [38] Cancer Genome Atlas Research Network Comprehensive genomic characterization of squamous cell lung cancers Nature 2012 489 7417 519 525 [published online September 27, 2012] 22960745 PMC3466113
- Not checked yetcites [39] D’Angelo SP Janjigian YY Ahye N Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib J Thorac Oncol 2012 7 12 1815 1822 23154553
- Not checked yetcites [40] Peifer M Fernández-Cuesta L Sos ML Integrative genome analyses identify key somatic driver mutations of small cell lung cancer Nat Genet 2012 44 10 1104 1110 22941188 PMC4915822
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The LCMC pathologists shared blinded samples, with a positive sample included for all 10 drivers.”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Methods > Interventions
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The multiplexed genotyping platforms made effective use of patient tissue and identified actionable drivers sooner, giving patient’s earlier access to therapies or trials.”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Discussion
plaindirectn = 18- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The presence of EGFR mutations defines a specific molecular subgroup of NSCLC (~15% of Caucasian patients with adenocarcinomas) [37, 38] that respond to an EGFR TKI in over 60% of patients (Table 1).”
From A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives (2015) · cites this paper as [38]
In the citing paper
“Somatic mutations in the kinase domain of the epidermal growth factor receptor (EGFR) gene are detected in approximately 40% and 17% of lung adenocarcinoma in Asians1 and in Caucasians,2 respectively.”
From Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy (2016) · cites this paper as [2]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Results
“Amplification of MET (MET/ CEP7 >2.2) was found in 5 of 733 patients’ tumors (<1%).”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Results
“In the full genotyping group, we found drivers in 2 genes in 24 tumors (3%). Of these 24 specimens, 20 (83%) included either a mutation in PIK3CA (n = 12) or MET amplification (n = 8).”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“Results were used to select a targeted therapy or trial in 275 of 1007 patients (28%).”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Abstract > RESULTS
Reported 28 · recomputed 27.308838
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Results
“We also recomputed the survival data excluding individuals with EGFR- and ALK-positive cancers. The 49 patients with oncogenic drivers other than EGFR or ALK who received a targeted therapy had a median survival of 4.9 years compared with the 678 with (318 patients) or without (360 patients) a driver identified, but not receiving a targeted agent, whose median survivals were 2.4 years with a driver (IQR, 0.88-6.20) and 2.1 years without (P = .14; eFigure 6 in the Supplement).”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Discussion
“survival analyses excluding these patients revealed that individuals with other drivers treated with targeted therapies still had an observed 2.5-year improvement in median survival over those who did not receive targeted therapy (eFigure 4 in the Supplement).”
Citations
Cites
Siegel, R., Ma, J., Zou, Z., & Jemal, A. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21208 · Cited by 11,499
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Self-citationGefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S. I., Dezube, B. J., Janne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,477
Self-citationPao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Self-citationComprehensive genomic characterization of squamous cell lung cancers
The Cancer Genome Atlas Research Network (2012) · Nature · doi:10.1038/nature11404 · Cited by 3,994
Self-citationSequist, L. V., Yang, J. C.-H., Yamamoto, N., O'Byrne, K., Hirsh, V., Mok, T., Geater, S. L., Orlov, S., Tsai, C.-M., Boyer, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.2806 · Cited by 3,228
Self-citationFirst-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer
Solomon, B. J., Mok, T., Kim, D.-W., Wu, Y.-L., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408440 · Cited by 3,190
Cited by
Sorted by citations
Items 101–200 of 1,000
The evolving landscape of biomarker testing for non-small cell lung cancer in Europe
Kerr, K. M., Bibeau, F., Thunnissen, E., Botling, J., Ryška, A., Wolf, J., Öhrling, K., Burdon, P., Malapelle, U., & Büttner, R. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.02.026 · Cited by 206
Kobayashi, Y., Togashi, Y., Yatabe, Y., Mizuuchi, H., Jangchul, P., Kondo, C., Shimoji, M., Sato, K., Suda, K., Tomizawa, K., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1046 · Cited by 203
Prevalence and detection of low-allele-fraction variants in clinical cancer samples
Shin, H., Choi, Y., Yun, J. W., Kim, N. K. D., Kim, S., Jeon, H. J., Nam, J., Lee, C., Ryu, D., Kim, S. C., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01470-y · Cited by 204
Chia, P. L., John, T., Dobrovic, A., & Mitchell, P. L. R. (2014) · Clinical Epidemiology · doi:10.2147/clep.s69718 · Cited by 203
Kron, A., Alidousty, C., Scheffler, M., Merkelbach-Bruse, S., Seidel, D., Riedel, R., Ihle, M. A., Michels, S., Nogova, L., Fassunke, J., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy333 · Cited by 197
Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer
Jee, J., Lebow, E. S., Yeh, R., Das, J. P., Namakydoust, A., Paik, P. K., Chaft, J. E., Jayakumaran, G., Brannon, A. R., Benayed, R., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02047-z · Cited by 201
Self-citationRemón, J., Rhun, É. L., & Besse, B. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.12.006 · Cited by 196
Smeltzer, M. P., Wynes, M. W., Lantuéjoul, S., Soo, R. A., Ramalingam, S. S., Varella‐Garcia, M., Taylor, M. M., Richeimer, K., Wood, K., Howell, K. E., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.05.002 · Cited by 196
Self-citationHorn, L., Infante, J. R., Reckamp, K. L., Blumenschein, G. R., Leal, T. A. B., Waqar, S. N., Gitlitz, B. J., Sanborn, R. E., Whisenant, J. G., Du, L., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2398 · Cited by 192
Rationale and Design of the Targeted Agent and Profiling Utilization Registry Study
Mangat, P. K., Halabi, S., Bruinooge, S. S., Garrett-Mayer, E. S., Alva, A. S., Janeway, K. A., Stella, P. J., Voest, E. E., Yost, K. J., Perlmutter, J., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.18.00122 · Cited by 199
Emerging Treatment Paradigms for EGFR-Mutant Lung Cancers Progressing on Osimertinib: A Review
Piper‐Vallillo, A. J., Sequist, L. V. D., & Piotrowska, Z. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03123 · Cited by 190
Self-citationALK-positive lung cancer: a moving target
Schneider, J. L., Lin, J. J., & Shaw, A. T. (2023) · Nature Cancer · doi:10.1038/s43018-023-00515-0 · Cited by 198
Lung Cancer in the Era of Precision Medicine
Politi, K. A., & Herbst, R. S. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2748 · Cited by 190
Automated Real-World Data Integration Improves Cancer Outcome Prediction
Jee, J., Fong, C., Pichotta, K., Tran, T. N., Luthra, A., Waters, M., Fu, C., Altoe, M., Liu, S.-Y., Maron, S. B., et al. (2024) · Nature · doi:10.1038/s41586-024-08167-5 · Cited by 188
Self-citationCurrent Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer
Blumenthal, G. M., Bunn, P. A., Chaft, J. E., McCoach, C. E., Perez, E. A., Scagliotti, G. V., Carbone, D. P., Aerts, H. J. W. L., Aisner, D. L., Bergh, J. C. S., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.09.017 · Cited by 188
Self-citationPrecision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience
Schwaederle, M. C., Parker, B. A., Schwab, R. B., Daniels, G. A., Piccioni, D. E., Kesari, S., Helsten, T. L., Bazhenova, L. A., Romero, J., Fanta, P. T., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0795 · Cited by 184
Yochum, Z. A., Cades, J., Wang, H., Chatterjee, S., Simons, B. W., O’Brien, J. P., Khetarpal, S. K., Lemtiri-Chlieh, G., Myers, K. V., Huang, E. H. ‐., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0482-y · Cited by 185
Self-citationRusso, A., Franchina, T., Rita Ricciardi, G. R., Picone, A., Ferraro, G., Zanghì, M., Toscano, G., Giordano, A., & Adamo, V. (2015) · Oncotarget · doi:10.18632/oncotarget.4254 · Cited by 173
Nahar, R., Zhai, W., Zhang, T., Takano, A., Khng, A. J., Lee, Y. Y., Liu, X., Lim, C. H., Koh, T. P. T., Aung, Z. W., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02584-z · Cited by 173
Management of brain metastases according to molecular subtypes
Soffietti, R., Ahluwalia, M. S., Lin, N., & Rudà, R. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0391-x · Cited by 175
Noonan, S. A., Berry, L. D., Lu, X. J. D., Gao, D., Barón, A. E., Chesnut, P., Sheren, J. E., Aisner, D. L., Merrick, D., Doebele, R. C., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.04.033 · Cited by 179
Self-citationFave, X. J., Mackin, D., Yang, J., Zhang, J., Fried, D., Balter, P. A., Followill, D. S., Gomez, D. R., Jones, A. K., Stingo, F. C., et al. (2015) · Medical Physics · doi:10.1118/1.4934826 · Cited by 171
Horn, L., Whisenant, J. G., Wakelee, H. A., Reckamp, K. L., Qiao, H., Leal, T. A. B., Du, L., Hernandez, J., Huang, V., Blumenschein, G. R., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.08.003 · Cited by 170
The evidence framework for precision cancer medicine
Moscow, J. A., Fojo, T., & Schilsky, R. L. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.186 · Cited by 169
BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall
Leonetti, A., Facchinetti, F., Rossi, G., Minari, R., Conti, A., Friboulet, L., Tiseo, M., & Planchard, D. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.04.006 · Cited by 179
Clinical Management of Adverse Events Associated with Lorlatinib
Bauer, T. M., Felip, E., Solomon, B., Thurm, H. C., Peltz, G., Chioda, M. D., & Shaw, A. T. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0380 · Cited by 173
Gerber, D. E., Camidge, D. R., Morgensztern, D., Cetnar, J., Kelly, R. J., Ramalingam, S. S., Spigel, D. R., Jeong, W., Scaglioni, P. P., Zhang, S., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2019.10.033 · Cited by 167
Self-citationwritten on behalf of AME Lung Cancer Collaborative Group, Xu, Y., Wan, B., Chen, X., Zhan, P., Zhao, Y., Zhang, T., Liu, H., Afzal, M. Z., Dermime, S., et al. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.08.09 · Cited by 170
Prioritizing targets for precision cancer medicine
André, F., Mardis, E. R., Salm, M. P., Soria, J., Siu, L. L., & Swanton, C. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu478 · Cited by 169
Tsimberidou, A. M., Hong, D. S., Ye, Y., Cartwright, C., Wheler, J. J., Falchook, G. S., Naing, A., Fu, S., Piha-Paul, S. A., Jankú, F., et al. (2017) · JCO Precision Oncology · doi:10.1200/po.17.00002 · Cited by 167
The Role of Next-Generation Sequencing in Precision Medicine: A Review of Outcomes in Oncology
Morash, M., Mitchell, H., Beltran, H., Elemento, O., & Pathak, J. (2018) · Journal of Personalized Medicine · doi:10.3390/jpm8030030 · Cited by 173
Challenges in molecular testing in non-small-cell lung cancer patients with advanced disease
Hiley, C. T., Quesne, J. P. C. L., Santis, G., Sharpe, R., de Castro, D. G., Middleton, G., & Swanton, C. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31340-x · Cited by 167
The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC)
Salgia, R., Pharaon, R. R., Mambetsariev, I., Nam, A., & Sattler, M. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100186 · Cited by 173
Prognostic and Predictive Value in KRAS in Non–Small-Cell Lung Cancer: A Review
Wood, K., Hensing, T., Malik, R., & Salgia, R. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.0405 · Cited by 164
Ha, S. Y., Choi, S., Cho, J. H., Choi, H. J., Lee, J., Jung, K., Irwin, D. L., Liu, X., Lira, M. E., Mao, M., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.2925 · Cited by 160
Molecular biomarkers for lung adenocarcinoma
Calvayrac, O., Pradines, A., Tostivint, E. P., Mazières, J., & Guibert, N. M. (2017) · European Respiratory Journal · doi:10.1183/13993003.01734-2016 · Cited by 160
Shea, M., Costa, D. B., & Rangachari, D. (2015) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465815617871 · Cited by 158
Emerging therapies for non-small cell lung cancer
Zhang, C., Leighl, N. B., Wu, Y.-L. L. C., & Zhong, W. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0731-8 · Cited by 159
Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer
Dang, T. O., Ogunniyi, A., Barbee, M. S., & Drilon, A. E. D. C. (2015) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2016.1123626 · Cited by 160
Jhaveri, K. L., Wang, X. V., Makker, V., Luoh, S.-W., Mitchell, E. P., Zwiebel, J. A., Sharon, E., Gray, R. J., Li, S., McShane, L. M., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz291 · Cited by 151
Personalized therapy for lung cancer: striking a moving target
Pakkala, S., & Ramalingam, S. S. (2018) · JCI Insight · doi:10.1172/jci.insight.120858 · Cited by 154
Biomarkers in colorectal cancer: Current clinical utility and future perspectives
Vacante, M., Borzì, A. M., Basile, F., & Biondi, A. (2018) · World Journal of Clinical Cases · doi:10.12998/wjcc.v6.i15.869 · Cited by 154
Schwaederle, M. C., Husain, H., Fanta, P. T., Piccioni, D. E., Kesari, S., Schwab, R. B., Banks, K. C., Lanman, R. B., Talasaz, A. H., Parker, B. A., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7110 · Cited by 151
Pacheco, J. M., Gao, D., Smith, D. E., Purcell, T., Hancock, M. J., Bunn, P. A., Robin, T. P., Liu, A. J., Karam, S. D., Gaspar, L. E., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.12.014 · Cited by 147
Self-citationThe Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV
Akamatsu, H., Ninomiya, K., Kenmotsu, H., Morise, M., Daga, H., Goto, Y., Kozuki, T., Miura, S., Sasaki, T., Tamiya, A., et al. (2019) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01431-z · Cited by 149
Kobayashi, Y., Mitsudomi, T., Sakao, Y., & Yatabe, Y. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu505 · Cited by 142
Molecular targeted therapy in the treatment of advanced stage non‐small cell lung cancer ( NSCLC )
Kumarakulasinghe, N. B., van Zanwijk, N., & Soo, R. A. (2015) · Respirology · doi:10.1111/resp.12490 · Cited by 145
Large-scale screening for somatic mutations in lung cancer
Rosell, R., & Karachaliou, N. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01125-3 · Cited by 142
Lamberti, G., Andrini, E., Sisi, M., Rizzo, A., Parisi, C., Federico, A. D., Gelsomino, F., & Ardizzoni, A. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103119 · Cited by 147
Hartmaier, R. J., Albacker, L. A., Chmielecki, J., Bailey, M., He, J., Goldberg, M. E., Ramkissoon, S. H., Suh, J. H., Elvin, J. A., Chiacchia, S., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2479 · Cited by 139
Precision oncology in the age of integrative genomics
Kumar‐Sinha, C., & Chinnaiyan, A. M. (2018) · Nature Biotechnology · doi:10.1038/nbt.4017 · Cited by 138
Presley, C. J., Tang, D., Soulos, P. R., Chiang, A. C., Longtine, J. A., Adelson, K. B., Herbst, R. S., Zhu, W., Nussbaum, N. C., Sorg, R. A., et al. (2018) · JAMA · doi:10.1001/jama.2018.9824 · Cited by 139
Goswami, R. S., Luthra, R., Singh, R. R., Patel, K. P., Routbort, M. J., Aldape, K., Yao, H., Dang, H., Barkoh, B. A., Manekia, J., et al. (2016) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqv023 · Cited by 135
Self-citationNext-Generation Assessment of Human Epidermal Growth Factor Receptor 2 (ERBB2) Amplification Status
Ross, D. S., Zehir, A., Cheng, D. T., Benayed, R., Nafa, K., Hechtman, J. F., Janjigian, Y. Y., Weigelt, B., Razavi, P., Hyman, D. M., et al. (2016) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2016.09.010 · Cited by 134
Self-citationNeal, J. W., Dahlberg, S. E., Wakelee, H. A., Aisner, S. C., Bowden, M., Huang, Y., Carbone, D. P., Gerstner, G. J., Lerner, R. E., Rubin, J. L., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30561-7 · Cited by 133
Clinical Characteristics and Course of 63 Patients with BRAF Mutant Lung Cancers
Litvak, A. M., Paik, P. K., Woo, K. M., Sima, C. S., Hellmann, M. D., Arcila, M. E., Ladanyi, M., Rudin, C. M., Kris, M. G., & Riely, G. J. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000344 · Cited by 132
Self-citationChemotherapy remains an essential element of personalized care for persons with lung cancers
Hellmann, M. D., Li, B., Chaft, J. E., & Kris, M. G. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw271 · Cited by 136
Self-citationCancer driver mutations: predictions and reality
Ostroverkhova, D. S., Przytycka, T. M., & Panchenko, A. R. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.03.007 · Cited by 147
Dagogo-Jack, I., Martinez, P., Yeap, B. Y., Ambrogio, C., Ferris, L. A., Lydon, C., Nguyen, T., Jessop, N. A., Iafrate, A. J., Johnson, B. E., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2062 · Cited by 130
Self-citationKawaguchi, T., Koh, Y., Ando, M., Ito, N., Takeo, S., Adachi, H., Tagawa, T., Kakegawa, S., Yamashita, M., Kataoka, K., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.2322 · Cited by 129
Uruga, H., Bozkurtlar, E. B., Huynh, T. G., Muzikansky, A., Goto, Y., Gomez‐Caraballo, M., Hata, A. N., Gainor, J. F., Mark, E. J., Engelman, J. A., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.10.015 · Cited by 133
Using circulating cell-free DNA to monitor personalized cancer therapy
Oellerich, M., Schütz, E., Beck, J., Kanzow, P., Plowman, P. N., Weiss, G. J., & Walson, P. D. (2017) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2017.1299683 · Cited by 133
Wen, S., Dai, L., Wang, L., Wang, W., Wu, D., Wang, K., He, Z., Wang, A., Chen, H., Zhang, P., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0572 · Cited by 131
Self-citationHsu, K.-H., Ho, C., Hsia, T., Tseng, J., Su, K., Wu, M., Chiu, K.-L., Yang, T., Chen, K.-C., Ooi, H., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0120852 · Cited by 127
Self-citationBRAF Alterations as Therapeutic Targets in Non–Small-Cell Lung Cancer
Nguyen‐Ngoc, T., Bouchaab, H., Adjei, A. A., & Peters, S. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000644 · Cited by 135
Isozaki, H., Ichihara, E., Takigawa, N., Ohashi, K., Ochi, N., Yasugi, M., Ninomiya, T., Yamane, H., Hotta, K., Sakai, K., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1010 · Cited by 128
Villaruz, L. C., Socinski, M. A., Abberbock, S. R., Berry, L. D., Johnson, B. E., Kwiatkowski, D. J., Iafrate, A. J., Varella‐Garcia, M., Franklin, W. A., Camidge, D. R., et al. (2014) · Cancer · doi:10.1002/cncr.29042 · Cited by 127
Self-citationShepherd, F. A., Lacas, B., Le Teuff, G., Hainaut, P., Jänne, P. A., Pignon, J.-P., Le Chevalier, T., Seymour, L., Douillard, J.-Y., Graziano, S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.2893 · Cited by 124
LCE: an open web portal to explore gene expression and clinical associations in lung cancer
Cai, L., Lin, S.-Y., Girard, L., Zhou, Y., Yang, L., Ci, B., Zhou, Q., Luo, D., Yao, B., Tang, H., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0588-2 · Cited by 125
Self-citationStinchcombe, T. E., Janne, P. A., Wang, X., Bertino, E. M., Weiss, J. M., Bazhenova, L. A., Gu, L., Lau, C. J., Paweletz, C. P., Jaslowski, A. J., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.1847 · Cited by 126
Cheng, Y., Zhang, T., & Xu, Q. (2021) · MedComm · doi:10.1002/mco2.105 · Cited by 131
Suzawa, K., Offin, M. D., Lu, D., Kurzatkowski, C., Vojnic, M., Smith, R. S., Sabari, J. K., Tai, H., Mattar, M. S., Khodos, I., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1640 · Cited by 129
Self-citationSMARCA4: Current status and future perspectives in non-small-cell lung cancer
Tian, Y., Xu, L., Li, X., Li, H., & Zhao, M. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.216022 · Cited by 123
Calles, A., Sholl, L. M., Rodig, S. J., Pelton, A. K., Hornick, J. L., Butaney, M., Lydon, C., Dahlberg, S. E., Oxnard, G. R., Jackman, D. M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3112 · Cited by 115
Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer
Nagano, T., TACHIHARA, M. Y., & Nishimura, Y. (2018) · Current Cancer Drug Targets · doi:10.2174/1568009619666181210114559 · Cited by 120
EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer
Fang, W., Huang, Y., Hong, S., Zhang, Z., Wang, M., Gan, J., Wang, W., Guo, H., Wang, K., & Zhang, L. (2019) · BMC Cancer · doi:10.1186/s12885-019-5820-0 · Cited by 120
Biomarker-Targeted Therapies in Non–Small Cell Lung Cancer: Current Status and Perspectives
Guo, H., Zhang, J., Qin, C., Yan, H., Liu, T., Hu, H., Tang, S., Tang, S., & Zhou, H. (2022) · Cells · doi:10.3390/cells11203200 · Cited by 123
König, D., Prince, S. S., & Rothschild, S. I. (2021) · Cancers · doi:10.3390/cancers13040804 · Cited by 119
Kim, E. Y., Cho, E. N., Park, H. S., Hong, J. Y., Lim, S., Youn, J. P., Hwang, S. Y., & Chang, Y. S. (2016) · Cancer Biology & Therapy · doi:10.1080/15384047.2016.1139235 · Cited by 117
Peters, S., Dziadziuszko, R., Morabito, A., Felip, E., Gadgeel, S. M., Cheema, P. K., Cobo, M., Andric, Z. G., Barrios, C. H., Yamaguchi, M., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01933-w · Cited by 122
Floc'h, N., Martin, M. J., Riess, J. W., Orme, J. P., Staniszewska, A. D., Ménard, L., Cuomo, M. E., O'Neill, D. J., Ward, R. A., Finlay, M. R. V., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0758 · Cited by 115
Targeted Therapies in Non-Small Cell Lung Cancer—Beyond EGFR and ALK
Rothschild, S. I. (2015) · Cancers · doi:10.3390/cancers7020816 · Cited by 117
Steuer, C. E., Behera, M., Berry, L. D., Kim, S., Rossi, M. R., Sica, G., Owonikoko, T. K., Johnson, B. E., Kris, M. G., Bunn, P. A., et al. (2015) · Cancer · doi:10.1002/cncr.29812 · Cited by 117
Self-citationSullivan, I., & Planchard, D. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2016.00076 · Cited by 119
Baik, C. S., Myall, N. J., & Wakelee, H. A. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0458 · Cited by 114
Awad, M. M., Leonardi, G. C., Kravets, S., Dahlberg, S. E., Drilon, A. E. D. C., Noonan, S. A., Camidge, D. R., Ou, S. I., Costa, D. B., Gadgeel, S. M., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.05.011 · Cited by 112
Self-citationTranscriptomics and solid tumors: The next frontier in precision cancer medicine
Tsimberidou, A. M., Fountzilas, E., Bleris, L. G., & Kurzrock, R. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.09.007 · Cited by 118
Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC).
Hall, R. D., Le, T. M., Haggstrom, D. E., & Gentzler, R. D. (2015) · PubMed · doi:10.3978/j.issn.2218-6751.2015.06.09 · Cited by 110
Facchinetti, F., Bluthgen, M. V., Tergemina-Clain, G., Faivre, L., Pignon, J., Planchard, D., Remón, J., Soria, J., Lacroix, L., & Besse, B. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.08.002 · Cited by 109
Porrello, A., Leslie, P. L., Harrison, E. B., Gorentla, B. K., Kattula, S., Ghosh, S. K., Azam, S. H., Holtzhausen, A., Chao, Y. L., Hayward, M. C., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04355-w · Cited by 110
Yang, Y., Li, L., Jiang, Z., Wang, B., & Pan, Z. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02641-5 · Cited by 113
Cell Type–Specific Adaptive Signaling Responses to KRASG12C Inhibition
Solanki, H. S., Welsh, E. A., Fang, B., Izumi, V., Darville, L., Stone, B., Franzese, R., Chavan, S., Kinose, F., Imbody, D., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3872 · Cited by 106
Self-citationChildress, M. A., Himmelberg, S. M., Chen, H., Deng, W., Davies, M. A., & Lovly, C. M. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0171 · Cited by 108
Self-citationEng, J., Woo, K. M., Sima, C. S., Plodkowski, A., Hellmann, M. D., Chaft, J. E., Kris, M. G., Arcila, M. E., Ladanyi, M., & Drilon, A. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000671 · Cited by 107
Self-citationRare cancers: a sea of opportunity
Boyd, N., Dancey, J. E., Gilks, C. B., & Huntsman, D. D. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00386-1 · Cited by 107
Ou, S. I., Schrock, A. B., Bocharov, E. V., Klempner, S. J., Haddad, C. K., Steinecker, G., Johnson, M. L., Gitlitz, B. J., Chung, J., Campregher, P. V., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.11.2224 · Cited by 106
Tan, O., Shrestha, R. N., Cunich, M. M., & SCHOFIELD, D. J. (2017) · Clinical Genetics · doi:10.1111/cge.13199 · Cited by 106
Naito, Y., Aburatani, H., Amano, T., Baba, E., Furukawa, T., Hayashida, T., Hiyama, E., Ikeda, S., Kanai, M., Kato, M., et al. (2020) · International Journal of Clinical Oncology · doi:10.1007/s10147-020-01831-6 · Cited by 108
Vendrell, J. A., Taviaux, S. A., Béganton, B., Godreuil, S., Audran, P., Grand, D., Clermont, E., Serre, I., Szablewski, V., Coopman, P. J., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-12679-8 · Cited by 103
Haslem, D. S., Norman, S. B. V., Fulde, G., Knighton, A. J., Belnap, T., Butler, A. M., Rhagunath, S., Newman, D. M., Gilbert, H., Tudor, B. P., et al. (2016) · Journal of Oncology Practice · doi:10.1200/jop.2016.011486 · Cited by 102
Metadata
- Authors
- Kris, M. G., Johnson, B. E., Berry, L. D., Kwiatkowski, D. J., Iafrate, A. J., Wistuba, I. I., Varella-Garcia, M., Franklin, W. A., Aronson, S. L., Su, P.-F., Shyr, Y., Camidge, D. R., Sequist, L. V., Glisson, B. S., Khuri, F. R., Garon, E. B., Pao, W., Rudin, C., Schiller, J., Haura, E. B., Socinski, M., Shirai, K., Chen, H., Giaccone, G., Ladanyi, M., Kugler, K., Minna, J. D., & Bunn, P. A.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Dana-Farber Cancer Institute (US)
- Vanderbilt University (US)
- Brigham and Women's Hospital (US)
- Massachusetts General Hospital (US)
- The University of Texas MD Anderson Cancer Center (US)
- University of Colorado Cancer Center Denver, Aurora
- University of Colorado Cancer Center (US)
- The Partners HealthCare Center for Personalized Genetic Medicine, Boston, Massachusetts
- Winship Cancer Institute (US)
- University of California, Los Angeles (US)
- Johns Hopkins University (US)
- The University of Texas Southwestern Medical Center (US)
- Moffitt Cancer Center (US)
- UPMC Hillman Cancer Center (US)
- Medical University of South Carolina (US)
- National Institutes of Health (US)
- Corresponding author
- Kris, Mark G.
- ORCID
- Kris, Mark G.
- Johnson, Bruce E.
- Berry, Lynne D.
- Kwiatkowski, David J.
- Iafrate, A. John
- Wistuba, Ignacio I.
- Shyr, Yu
- Camidge, D. Ross
- Sequist, Lecia V.
- Glisson, Bonnie S.
- Khuri, Fadlo R.
- Garon, Edward B.
- Pao, William
- Rudin, Charles
- Schiller, Joan
- Haura, Eric B.
- Socinski, Mark
- Shirai, Keisuke
- Chen, Heidi
- Giaccone, Giuseppe
- Ladanyi, Marc
- Minna, John D.
- Bunn, Paul A.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2014-05-21
- Volume
- 311
- Issue
- 19
- Pages
- 1998
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- PMC
- PMC4163053
- OpenAlex
- W2065477010
- Semantic Scholar
- 07fff1c9d77fb2b8731d7d86b38c7ac05df654c7
- Cited by
- 1,724
- References
- 69
- Citations by year
- 2026: 55 · 2025: 99 · 2024: 101 · 2023: 116 · 2022: 164 · 2021: 171 · 2020: 173 · 2019: 137 · 2018: 186 · 2017: 162 · 2016: 173 · 2015: 146 · 2014: 37
- FWCI
- 138.25
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (UL1TR000124)
- National Cancer Institute (RC2CA148394, K23CA149079, P01CA129243, 1RC2CA148394‐010, P50CA058187, P30CA008748, P30CA016672, P30CA046934)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- lung adenocarcinoma, oncogenic drivers, targeted therapy, multiplex genotyping, KRAS, EGFR, ALK rearrangement, BRAF, PIK3CA, ERBB2, MET amplification, NRAS, MEK1, AKT1, metastatic lung cancer, survival, genotype-directed therapy, clinical trial recruitment
- MeSH terms
- Adenocarcinoma of Lung, Adenocarcinoma, Aged, Female, Genotype, Humans, Lung Neoplasms, Male, Middle Aged, Proto-Oncogenes, Survival Analysis, Sequence Analysis, DNA, Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization, Molecular Targeted Therapy, Multiplex Polymerase Chain Reaction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
